(Q64892305)

30 June 2019

2 references

8 February 2021

31 July 2022

Mutant p53 in cancer therapy-the barrier or the path. (English)

1 reference

30 June 2019

1 reference

8 February 2021

Xiang Zhou

1

1 reference

30 June 2019

Qian Hao

series ordinal

2

1 reference

30 June 2019

Hua Lu

series ordinal

3

1 reference

30 June 2019

publication date

1 April 2019

3 references

30 June 2019

Journal of Molecular Cell Biology

8 February 2021

31 July 2022

3 references

30 June 2019

8 February 2021

31 July 2022

11

1 reference

30 June 2019

issue

4

1 reference

30 June 2019

page(s)

293-305

1 reference

30 June 2019

Creative Commons Attribution-NonCommercial 4.0 International

copyright license

2 references

8 February 2021

Wild-type p53 is a cell cycle checkpoint determinant following irradiation

31 July 2022

cites work

1 reference

12 December 2020

Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.

1 reference

12 December 2020

High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene

1 reference

12 December 2020

Participation of p53 cellular tumour antigen in transformation of normal embryonic cells

1 reference

12 December 2020

Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53

1 reference

12 December 2020

Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation.

1 reference

12 December 2020

Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy

1 reference

12 December 2020

Geldanamycin selectively destabilizes and conformationally alters mutated p53

1 reference

12 December 2020

Preferential overexpression of a 172Arg-->Leu mutant p53 in the mammary gland of transgenic mice results in altered lobuloalveolar development

1 reference

12 December 2020

p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies

1 reference

12 December 2020

p53 status and the efficacy of cancer therapy in vivo

1 reference

12 December 2020

Gain of function mutations in p53.

1 reference

12 December 2020

Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer

1 reference

12 December 2020

The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53.

1 reference

12 December 2020

p53 mutations increase resistance to ionizing radiation

1 reference

12 December 2020

The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers

1 reference

12 December 2020

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

1 reference

12 December 2020

Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.

1 reference

12 December 2020

p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma

1 reference

12 December 2020

Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas

1 reference

12 December 2020

Role of p53 in drug resistance in ovarian cancer

1 reference

12 December 2020

neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice

1 reference

12 December 2020

Myeloproliferative disease and myelodysplastic syndrome induced by transplantation of bone marrow cells expressing mutant p53

1 reference

12 December 2020

Changes in p53 expression can modify cell shape of ras-transformed fibroblasts and epitheliocytes.

1 reference

12 December 2020

The mouse equivalent of the human p53ser249 mutation p53ser246 enhances aflatoxin hepatocarcinogenesis in hepatitis B surface antigen transgenic and p53 heterozygous null mice

1 reference

12 December 2020

Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations.

1 reference

12 December 2020

Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain

1 reference

12 December 2020

p73 function is inhibited by tumor-derived p53 mutants in mammalian cells.

1 reference

12 December 2020

Pharmacological rescue of mutant p53 conformation and function

1 reference

12 December 2020

A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain

1 reference

12 December 2020

Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization

1 reference

12 December 2020

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

1 reference

12 December 2020

Wild-type p53 induced sensitization of mutant p53 TNF-resistant cells: role of caspase-8 and mitochondria

1 reference

12 December 2020

Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice.

1 reference

12 December 2020

On respiratory impairment in cancer cells

1 reference

12 December 2020

Prostate-specific expression of p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival.

1 reference

12 December 2020

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

1 reference

12 December 2020

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.

1 reference

12 December 2020

PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis.

1 reference

12 December 2020

Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors

1 reference

12 December 2020

The concept of synthetic lethality in the context of anticancer therapy

1 reference

12 December 2020

Identification of a novel germ line variant hotspot mutant p53-R175L in pediatric adrenal cortical carcinoma

1 reference

12 December 2020

Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells

1 reference

12 December 2020

Autophagy and cancer therapy

1 reference

12 December 2020

Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation

1 reference

12 December 2020

The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity

1 reference

12 December 2020

p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.

1 reference

12 December 2020

Chromosome fragile sites

1 reference

12 December 2020

Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex

1 reference

12 December 2020

A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis

1 reference

12 December 2020

An oncogene-induced DNA damage model for cancer development

1 reference

12 December 2020

Transcriptional control of human p53-regulated genes

1 reference

12 December 2020

The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss

1 reference

12 December 2020

Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families

1 reference

12 December 2020

Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy.

1 reference

12 December 2020

Mutant p53 protein localized in the cytoplasm inhibits autophagy

1 reference

12 December 2020

The genetics of the p53 pathway, apoptosis and cancer therapy

1 reference

12 December 2020

Identification of GRO1 as a critical determinant for mutant p53 gain of function

1 reference

12 December 2020

A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis

1 reference

12 December 2020

Cytoplasmic functions of the tumour suppressor p53.

1 reference

12 December 2020

PRIMA-1 reactivates mutant p53 by covalent binding to the core domain

1 reference

12 December 2020

Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells

1 reference

12 December 2020

Understanding the Warburg effect: the metabolic requirements of cell proliferation

1 reference

12 December 2020

Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model

1 reference

12 December 2020

Autophagic cell death induced by 5-FU in Bax or PUMA deficient human colon cancer cell

1 reference

12 December 2020

The first 30 years of p53: growing ever more complex

1 reference

12 December 2020

20 years studying p53 functions in genetically engineered mice

1 reference

12 December 2020

Mutant p53 drives invasion by promoting integrin recycling

1 reference

12 December 2020

Genomic instability--an evolving hallmark of cancer

1 reference

12 December 2020

Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function

1 reference

12 December 2020

Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells

1 reference

12 December 2020

Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA.

1 reference

12 December 2020

Targeting the dynamic HSP90 complex in cancer

1 reference

12 December 2020

Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells

1 reference

12 December 2020

Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures.

1 reference

12 December 2020

Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action

1 reference

12 December 2020

p53 and its mutants in tumor cell migration and invasion

1 reference

12 December 2020

Wild-type and mutant p53 proteins interact with mitochondrial caspase-3

1 reference

12 December 2020

Hallmarks of Cancer: The Next Generation

1 reference

12 December 2020

Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells

1 reference

12 December 2020

p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2.

1 reference

12 December 2020

Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism

1 reference

12 December 2020

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

1 reference

12 December 2020

Integrated genomic analyses of ovarian carcinoma

1 reference

12 December 2020

A Pin1/mutant p53 axis promotes aggressiveness in breast cancer

1 reference

12 December 2020

TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73.

1 reference

12 December 2020

MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function

1 reference

12 December 2020

Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway

1 reference

12 December 2020

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8.

1 reference

12 December 2020

Mutant p53 cooperates with ETS2 to promote etoposide resistance

1 reference

12 December 2020

Allele-specific p53 mutant reactivation

1 reference

12 December 2020

Mutant p53: one name, many proteins

1 reference

12 December 2020

Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis.

1 reference

12 December 2020

Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species

1 reference

12 December 2020

Drastic effect of germline TP53 missense mutations in Li-Fraumeni patients

1 reference

12 December 2020

Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9

1 reference

12 December 2020

Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.

1 reference

12 December 2020

Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche

1 reference

12 December 2020

Novel monofunctional platinum (II) complex Mono-Pt induces apoptosis-independent autophagic cell death in human ovarian carcinoma cells, distinct from cisplatin

1 reference

12 December 2020

Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells.

1 reference

12 December 2020

Small molecule induced reactivation of mutant p53 in cancer cells

1 reference

12 December 2020

Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.

1 reference

12 December 2020

Chaperone-mediated autophagy degrades mutant p53.

1 reference

12 December 2020

Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment

1 reference

12 December 2020

APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

1 reference

12 December 2020

Tumour-associated mutant p53 drives the Warburg effect

1 reference

12 December 2020

Self-consumption: the interplay of autophagy and apoptosis

1 reference

12 December 2020

Li-Fraumeni syndrome: cancer risk assessment and clinical management

1 reference

12 December 2020

Mutant p53 in cancer: new functions and therapeutic opportunities

1 reference

12 December 2020

Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation.

1 reference

12 December 2020

Tackling the cancer stem cells - what challenges do they pose?

1 reference

12 December 2020

PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

1 reference

12 December 2020

SIRT1 regulates oncogenesis via a mutant p53-dependent pathway in hepatocellular carcinoma

1 reference

12 December 2020

Inhibition of oxidative metabolism leads to p53 genetic inactivation and transformation in neural stem cells

1 reference

12 December 2020

The p53 isoform Δ133p53β promotes cancer stem cell potential

1 reference

12 December 2020

Mutant p53 promotes tumor cell malignancy by both positive and negative regulation of the transforming growth factor β (TGF-β) pathway

1 reference

12 December 2020

Tissue invasion and metastasis: Molecular, biological and clinical perspectives

1 reference

12 December 2020

Hitting cancers' weak spots: vulnerabilities imposed by p53 mutation

1 reference

12 December 2020

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment

1 reference

12 December 2020

Whole-genome characterization of chemoresistant ovarian cancer

1 reference

12 December 2020

p53 Deletion or Hotspot Mutations Enhance mTORC1 Activity by Altering Lysosomal Dynamics of TSC2 and Rheb

1 reference

12 December 2020

DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53

1 reference

12 December 2020

A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas

1 reference

12 December 2020

Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells

1 reference

12 December 2020

Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition.

1 reference

12 December 2020

COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo.

1 reference

12 December 2020

Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation

1 reference

12 December 2020

Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth.

1 reference

12 December 2020

Nerve growth factor receptor negates the tumor suppressor p53 as a feedback regulator

1 reference

12 December 2020

Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer.

1 reference

12 December 2020

Targeting WEE1 Kinase in Cancer

1 reference

12 December 2020

2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells

1 reference

12 December 2020

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

1 reference

12 December 2020

HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer.

1 reference

12 December 2020

Molecular interplay between mutant p53 proteins and autophagy in cancer cells.

1 reference

12 December 2020

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months

1 reference

12 December 2020

Pleckstrin homology domain-containing protein PHLDB3 supports cancer growth via a negative feedback loop involving p53.

1 reference

12 December 2020

Negative auto-regulators trap p53 in their web.

1 reference

12 December 2020

Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP/TAZ.

1 reference

12 December 2020

p53 and its mutants on the slippery road from stemness to carcinogenesis

1 reference

12 December 2020

Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation

1 reference

12 December 2020

Molecularly targeted therapies for p53-mutant cancers

1 reference

12 December 2020

Mutant p53 as a target for cancer treatment.

1 reference

12 December 2020

Putting p53 in Context

1 reference

12 December 2020

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

1 reference

12 December 2020

Mutant p53 partners in crime

1 reference

12 December 2020

Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding

1 reference

12 December 2020

Targeting mutant p53 for efficient cancer therapy.

1 reference

12 December 2020

Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers.

1 reference

12 December 2020

Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1α.

1 reference

12 December 2020

USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells.

1 reference

12 December 2020

Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells.

1 reference

12 December 2020

Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases

1 reference

12 December 2020

It Takes a Team: A Gain-of-function Story of p53-R249S

1 reference

12 December 2020

Identifiers

DOI

10.1093/JMCB/MJY072

1 reference

30 June 2019

PMC publication ID

6487791

1 reference

30 June 2019

PubMed publication ID

30508182

1 reference

30 June 2019